Protocol Ledger

NCT04939090 · Phase III · ACTIVE NOT RECRUITING

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Interventional Phase III clinical trial protocol NCT04939090 sponsored by Alliance for Clinical Trials in Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-01-03 Enrollment: 227 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04939090
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)227 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04939090
Protocol FieldVerified Registry Value
NCT IdentifierNCT04939090
Consolidated Lead SponsorAlliance for Clinical Trials in Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment227 participants (ACTUAL)
Registered Start Date2022-01-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04939090
Hospital Research SiteLocationSite Profile
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - JonesboroJonesboro, AROpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI